Sientra Inc (NASDAQ:SIEN) has earned a consensus rating of “Buy” from the twelve research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $15.75.

Several equities research analysts have recently commented on SIEN shares. Stephens set a $16.00 target price on shares of Sientra and gave the stock a “buy” rating in a research report on Friday, August 9th. Craig Hallum lowered their price objective on Sientra from $20.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, July 25th. ValuEngine upgraded Sientra from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Canaccord Genuity lifted their target price on Sientra from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Wells Fargo & Co upgraded Sientra from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $8.00 to $10.00 in a report on Wednesday, June 5th.

Shares of NASDAQ SIEN traded up $0.07 during trading on Friday, hitting $7.15. 38,613 shares of the company traded hands, compared to its average volume of 756,854. The business’s fifty day moving average is $6.36 and its 200 day moving average is $7.36. Sientra has a fifty-two week low of $4.78 and a fifty-two week high of $25.77. The firm has a market capitalization of $326.31 million, a price-to-earnings ratio of -2.20 and a beta of 0.25. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.99 and a current ratio of 2.33.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.50). The firm had revenue of $20.53 million during the quarter, compared to the consensus estimate of $19.04 million. Sientra had a negative return on equity of 123.80% and a negative net margin of 151.96%. The firm’s revenue was up 17.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.73) EPS. On average, analysts predict that Sientra will post -2.35 EPS for the current year.

Several institutional investors have recently bought and sold shares of SIEN. Bank of America Corp DE lifted its holdings in Sientra by 82.1% during the fourth quarter. Bank of America Corp DE now owns 50,770 shares of the medical instruments supplier’s stock worth $646,000 after acquiring an additional 22,888 shares during the period. Deutsche Bank AG increased its holdings in Sientra by 76.6% during the fourth quarter. Deutsche Bank AG now owns 82,036 shares of the medical instruments supplier’s stock worth $1,042,000 after buying an additional 35,584 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in Sientra by 97,300.0% during the first quarter. BNP Paribas Arbitrage SA now owns 4,870 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 4,865 shares during the last quarter. Stephens Inc. AR raised its position in Sientra by 155.1% in the first quarter. Stephens Inc. AR now owns 140,700 shares of the medical instruments supplier’s stock worth $1,207,000 after acquiring an additional 85,550 shares during the period. Finally, Formula Growth Ltd. raised its position in Sientra by 9.1% in the first quarter. Formula Growth Ltd. now owns 120,000 shares of the medical instruments supplier’s stock worth $1,030,000 after acquiring an additional 10,000 shares during the period. 88.96% of the stock is currently owned by hedge funds and other institutional investors.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: What does it mean to hold a stock in street name?

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.